Oncology eCOA: What the New FDA Draft Guidelines Tell Us

Date Published:

Signant’s in-house experts, Dr. Bill Byrom and Dr. Jill Platko, discuss the key takeaways from the FDA’s recent draft guidelines. You’ll learn everything you need to know regarding patient-reported outcome in oncology studies.

Watch the webinar recording to learn:  

  • Current patient-reported outcome measures (PROMs) labelling & oncology challenges
  • How to address PROM specificitiy: core measurement domains
  • Ideal measurement timing & frequency
  • Changes needed for eCOA design and implementation

Do you still have questions regarding eCOA use for oncology studies? Contact our team and we’ll ensure you’re properly prepared to meet FDA expectations.